Wells Fargo analyst Tiago Fauth raised the firm’s price target on BridgeBio (BBIO) to $67 from $58 and keeps an Overweight rating on the shares. The firm notes 1,028 unique patients imply new patients per week grew about 30% in the five weeks since the last update, indicating that prescription growth is accelerating. Wells increases its Attruby numbers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $49 from $45 at Citi
- Positive Outlook for BridgeBio Pharma Due to Accelerating Patient Growth and Promising Drug Pipeline
- BridgeBio Pharma Reports Strong 2024 Financial Results
- BridgeBio Pharma’s Growth Potential and Strategic Positioning: A Buy Recommendation by Tyler Van Buren
- BridgeBio price target raised to $95 from $70 at Cantor Fitzgerald